<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914289</url>
  </required_header>
  <id_info>
    <org_study_id>EHBH-RCT-2013-002-02</org_study_id>
    <nct_id>NCT01914289</nct_id>
  </id_info>
  <brief_title>Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients</brief_title>
  <official_title>Comparison of Resection and Radiotherapy in the Prognosis of Intrahepatic Cholangiocarcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Hepatobiliary Surgery Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm that prognosis of Intrahepatic Cholangiocarcinoma
      (ICC) with resection and radiotherapy ,to find which is safe and effective treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intrahepatic Cholangiocarcinoma (ICC), the second most common primary liver cancer and
      constitutes 10% of primary liver malignancies.

      Current therapies for the treatment of ICC are ineffective and the role of liver
      transplantation is not well defined.

      This study reviews our experience with this tumor and looks for preoperative and pathologic
      indices that may help determine long term prognosis
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the overall survival rate of each group</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Resection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To observe prognosis of resection of icc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To observe the prognosis of radiotherapy treatment of icc</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resection</intervention_name>
    <arm_group_label>Resection</arm_group_label>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Resection</arm_group_label>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients &gt; 17 years and &lt;=60 years of age. confirmed case (patients
             with ICC) Tumors can be radical removed and resection volume was ≤50%. Criteria of
             liver function: Child A level, serum bilirubin ≤ 1.5 times the upper limit of normal
             value,alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper
             limit of normal value.

        No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung
        function are basically normal. Hbg ≥ 90g/L, WBC ≥ 3.000 cells/mm³,platelets ≥ 80.000
        cells/mm³.

        Karnofsky Performance Score performance over 60. Patients who can understand this trial and
        have signed information consent.

        Exclusion Criteria:

          -  Patients who have undergone previous treatment by Resection or Radiotherapy. Patients
             with apparent cardiac, pulmonary, cerebronic and renal dysfunction, which may affect
             the treatment of liver cancer.

        Patients with other diseases which may affect the treatment mentioned here. Patients with
        medical history of other malignant tumors. Subjects participating in other clinical trials.
        Extrahepatic metastasis, portal vein or other major vascular involvement. liver function:
        Child B C.

        Patients would not sign the consent to the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Aijun, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Aijun, MD</last_name>
    <phone>86-21-81875531</phone>
    <email>ajli62@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuan Hang</last_name>
    <phone>86-21-81875531</phone>
    <email>yuanhang8106@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Aijun, MD</last_name>
      <phone>86-21-81875531</phone>
      <email>ajli62@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yuan Hang, doctor</last_name>
      <phone>86-21-81875531</phone>
      <email>yuanhang8106@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2013</study_first_submitted>
  <study_first_submitted_qc>August 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Hepatobiliary Surgery Hospital</investigator_affiliation>
    <investigator_full_name>ShenFeng</investigator_full_name>
    <investigator_title>director of department of special treatment</investigator_title>
  </responsible_party>
  <keyword>Intrahepatic Cholangiocarcinoma</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Resection</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

